| Stereochemistry | MIXED |
| Molecular Formula | C26H25N2O6S.Na |
| Molecular Weight | 516.541 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(=O)OC3=CC=C4CCCC4=C3)C5=CC=CC=C5)C([O-])=O
InChI
InChIKey=QFWPXOXWAUAYAB-XZVIDJSISA-M
InChI=1S/C26H26N2O6S.Na/c1-26(2)20(24(31)32)28-22(30)19(23(28)35-26)27-21(29)18(15-7-4-3-5-8-15)25(33)34-17-12-11-14-9-6-10-16(14)13-17;/h3-5,7-8,11-13,18-20,23H,6,9-10H2,1-2H3,(H,27,29)(H,31,32);/q;+1/p-1/t18?,19-,20+,23-;/m1./s1
| Molecular Formula | C26H25N2O6S |
| Molecular Weight | 493.552 |
| Charge | -1 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Originator
Approval Year
Doses
AEs
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as victim
Sourcing
Sample Use Guides
Usual Adult Dose
URINARY TRACT INFECTIONS: Escherichia coli, Proteus species and Enterobacter: 1–2 tablets 4 times daily
Pseudomonas and Enterococcus: 2 tablets 4 times daily
PROSTATITIS Escherichia coli, Proteus mirabilis, Enterobacter and Enterococcus: 2 tablets 4 times daily
Route of Administration:
Oral
The activity of carbenicillin against 200 strains of Pseudomonas aeruginosa was measured by a quantitative agar dilution method. Carbenicillin 300 mug. per ml. exerted appreciable bactericidal effect against nine of 15 strains of Ps. aeruginosa after a 24-hour contact period; after only six hours the bactericidal effect was very small. Quantitative sensitivity measurements for carbenicillin should include minimal inhibitory concentrations (M.I.C.'s) values for both complete inhibition (CI) and reduced growth (RG) criteria, using a range of inocula for testing. Such M.I.C. values may well be useful in monitoring carbenicillin therapy of tissue infections.
